Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.06 on Friday. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $7.51. The stock has a 50 day simple moving average of $0.06 and a two-hundred day simple moving average of $0.05. The company has a market cap of $690,995.00, a P/E ratio of -0.07 and a beta of 0.69.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.